SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model
ABSTRACT Effective clinical intervention strategies for COVID-19 are urgently needed. Although several clinical trials have evaluated the use of convalescent plasma containing virus-neutralizing antibodies, the effectiveness has not been proven. We show that hamsters treated with a high dose of human convalescent plasma or a monoclonal antibody were protected against weight loss showing reduced pneumonia and pulmonary virus replication compared to control animals. However, a ten-fold lower dose of convalescent plasma showed no protective effect. Thus, variable and relatively low levels of virus neutralizing antibodies in convalescent plasma may limit their use for effective antiviral therapy, favouring concentrated, purified (monoclonal) antibodies..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
bioRxiv.org - (2022) vom: 09. Nov. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Haagmans, Bart L. [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2020.08.24.264630 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI018632769 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI018632769 | ||
| 003 | DE-627 | ||
| 005 | 20230429082238.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200827s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.08.24.264630 |2 doi | |
| 035 | |a (DE-627)XBI018632769 | ||
| 035 | |a (biorXiv)10.1101/2020.08.24.264630 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Haagmans, Bart L. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Effective clinical intervention strategies for COVID-19 are urgently needed. Although several clinical trials have evaluated the use of convalescent plasma containing virus-neutralizing antibodies, the effectiveness has not been proven. We show that hamsters treated with a high dose of human convalescent plasma or a monoclonal antibody were protected against weight loss showing reduced pneumonia and pulmonary virus replication compared to control animals. However, a ten-fold lower dose of convalescent plasma showed no protective effect. Thus, variable and relatively low levels of virus neutralizing antibodies in convalescent plasma may limit their use for effective antiviral therapy, favouring concentrated, purified (monoclonal) antibodies. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Noack, Danny |e verfasserin |4 aut | |
| 700 | 1 | |a Okba, Nisreen M.A. |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Wentao |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chunyan |e verfasserin |4 aut | |
| 700 | 1 | |a Bestebroer, Theo |e verfasserin |4 aut | |
| 700 | 1 | |a de Vries, Rory |e verfasserin |4 aut | |
| 700 | 1 | |a Herfst, Sander |e verfasserin |4 aut | |
| 700 | 1 | |a de Meulder, Dennis |e verfasserin |4 aut | |
| 700 | 1 | |a van Run, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Lamers, Mart M. |e verfasserin |4 aut | |
| 700 | 1 | |a Rijnders, Bart |e verfasserin |4 aut | |
| 700 | 1 | |a Rokx, Casper |e verfasserin |4 aut | |
| 700 | 1 | |a van Kuppeveld, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Grosveld, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Drabek, Dubravka |e verfasserin |4 aut | |
| 700 | 1 | |a GeurtsvanKessel, Corine |e verfasserin |4 aut | |
| 700 | 1 | |a Koopmans, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Bosch, Berend Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Kuiken, Thijs |e verfasserin |4 aut | |
| 700 | 1 | |a Rockx, Barry |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2022) vom: 09. Nov. |
| 773 | 1 | 8 | |g year:2022 |g day:09 |g month:11 |
| 856 | 4 | 0 | |u https://doi.org/10.1093/infdis/jiab289 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.08.24.264630 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 09 |c 11 | ||